chicago: may 2014
Acelarin achieves high disease control rate in patients with advanced cancer. ProGem1 study results presented at the ASCO 50th Annual Meeting.
edinburgh: april 2014
NuCana announces a Series B financing of $57 million to fund expansion of clinical studies with its anti-cancer ProTides.
san diego: April 2014
NuCana presents exceptional data for anti-cancer agent, Acelarin, at the AACR Annual Meeting.